New treatment for hair loss shows promise — paid volunteers needed to test it out
I can tell you that VDPHL01 has a unique profile unlike current FDA-approved treatments, which are associated with cardiac ...
FDA approves HCW Biologics trial for alopecia treatment
MIRAMAR, Fla. - HCW Biologics Inc. (NASDAQ: HCWB), a clinical-stage biopharmaceutical company with a market capitalization of approximately $12.4 million, announced today that it has received U.S.
Too Old to Operate10d
FDA Approved Dermatologic Therapies in 2024
The following is a summary of “A year in review: new treatments and expanded indications in dermatology in 2024,” published in the January 2025 issue of Dermatology by McGrath et al. In 2024, ...
Healthline5d
Olumiant: How It’s Used for Treating Alopecia
Olumiant (baricitinib) is a prescription drug used to treat severe alopecia areata. It’s typically used when hair loss from this condition affects more than 50% of the scalp. Olumiant is a brand ...
HCW Biologics Granted FDA Clearance to Evaluate One of the Company’s Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial
Wong, Founder and CEO of HCW Biologics, commented, “The FDA’s clearance to initiate our first-in-human clinical trial for HCW9302 brings us one step closer to advancing a potentially transformative ...
HCW Biologics receives clearance of IND from FDA for HCW9302
HCW Biologics (HCWB) announced that it has received clearance of its Investigational New Drug Application, IND, from the U.S. Food and Drug ...
Investing8d
FDA approves HCW Biologics trial for alopecia treatment
clearance to commence a Phase 1 clinical trial for its drug candidate HCW9302, aimed at treating moderate-to-severe alopecia areata, an autoimmune condition causing hair loss. The company's stock ...